Net profit was lower than the ₹8,155 crore reported a year ago, which in turn was almost entirely due to an exceptional gain of ₹7,614 crore from the demerger of the pharmaceutical business.
Indian companies are experiencing a decline in shareholder dissent, with resolutions facing over 20% opposition from institutional investors dropping to 16% this fiscal year. Increased
India witnessed its lowest monthly increase in demat accounts this financial year, adding 3.5 million in October, as market volatility, fueled by overseas fund withdrawals
Advertiser Disclosure
Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.
Disclaimer
It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information
Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003